- Home
- MRK vs JLS Comparison
MRK vs JLS Comparison
Compare MRK & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRK | JLS |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.7B | 98.2M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRK | JLS |
|---|---|---|
| Price | $120.27 | $18.26 |
| Analyst Decision | Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $123.67 | N/A |
| AVG Volume (30 Days) | ★ 6.6M | 15.2K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | 2.81% | ★ 9.33% |
| EPS Growth | ★ 8.01 | N/A |
| EPS | ★ 7.28 | N/A |
| Revenue | ★ $65,011,000,000.00 | N/A |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $5.47 | N/A |
| P/E Ratio | $16.56 | ★ N/A |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $75.40 | $16.80 |
| 52 Week High | $125.14 | $19.09 |
Technical Indicators
Market Signals| Indicator | MRK | JLS |
|---|---|---|
| Relative Strength Index (RSI) | 59.95 | 55.25 |
| Support Level | $113.27 | $18.25 |
| Resistance Level | $125.14 | $18.89 |
| Average True Range (ATR) | 2.40 | 0.36 |
| MACD | 0.49 | 0.05 |
| Stochastic Oscillator | 86.06 | 77.78 |
Price Performance
Historical ComparisonAbout MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.